FGFR-IN-11 CAS No.: 2658488-68-5

Chemical Structure : FGFR-IN-11

CAS No.: 2658488-68-5

 

FGFR-IN-11

Catalog No.: URK-V2507 Only Used For Lab.

FGFR-IN-11 is a novel small molecule inhibitor of fibroblast growth factor receptor (FGFR).

Biological Activity

FGFR-IN-11 is a novel small molecule inhibitor of fibroblast growth factor receptor (FGFR).
FGFR is a transmembrane receptor tyrosine kinase that plays a crucial role in various biological processes such as cell differentiation, proliferation, and migration. Aberrant FGFR signaling has been implicated in the development of a wide range of diseases including cancer, cardiovascular disease, and bone disorders.
FGFR-IN-11 works by binding to the ATP-binding pocket of FGFR, inhibiting the phosphorylation of the receptor and downstream signaling pathways. This inhibition leads to the suppression of cell proliferation and induction of apoptosis in cancer cells.
Recent studies have shown that FGFR-IN-11 has potent anti-cancer activity against a variety of cancer cell lines including lung cancer, breast cancer, and multiple myeloma. Moreover, it has shown promising results in preclinical animal models, displaying strong anti-tumor effects with little toxicity.

Physicochemical Properties

References

1. Kümper S, et al. FGFR inhibitors: A patent review (2011 - 2015). Expert Opin Ther Pat. 2016;26(12):1351-1363.

2. Zhao G, et al. FGFR inhibitors: A new targeted therapy for cancer. Cancer Lett. 2015;379(2):99-109.

3. Yuan L, et al. FGFR inhibitors: A patent review (2016-present). Expert Opin Ther Pat. 2020;30(2):81-91.

URK-V2507_COA

URk-V2507_SDS

URK-V2507_TDS

Hot Tags: FGFR-IN-11 CAS No.: 2658488-68-5, China FGFR-IN-11 CAS No.: 2658488-68-5, epigenetic library for epigenetic analysis of epigenetic diversity, epigenetic library for epigenetic crosstalk, epigenetic library for epigenetic regulation of cell migration, inhibitors for drug delivery, epigenetic library for epigenetic determination of cell identity, epigenetic library for epigenetic analysis of epigenetic biomarker validation